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In Reply Dr Goldman and colleagues highlight aspects of the
phylogenetic analyses used to investigate HIV transmission
events in the PARTNER study.1 Previous studies have taken
advantage of the now-discontinued Roche 454 deep-
sequencing platform to obtain sequence reads of sufficient
length to allow reliable phylogenetic analyses of minority
viral species. We have been conducting work to optimize
the Illumina deep-sequencing platform to perform an analy-
sis of minority species in couples in our study. The recon-
struction of HIV haplotypes presents notorious technical
and interpretative challenges when applied to the short
sequence reads currently obtained by Illumina. We are also
using conventional limiting dilution techniques to obtain
single and near full-length genomes using established
methods.2 These further analyses will be submitted for pub-
lication once completed.
Also, Goldman and colleagues propose that some env
pairwise genetic distances in samples from the PARTNER
study were similar to those of samples found to be linked in
another study.3 The proposed comparison of genetic dis-
tances is complicated by the fact that the sequences in the
PARTNER study were considerably longer (2000 base pairs)
than those reported in the other study (approximately 516
base pairs). Nonetheless, as shown in eTable 2 in the article
Supplement, the median pairwise distance of env control
sequences was at least 5 times lower than the median pair-
wise distance of the partners’ env sequences. When consid-
ering sequences falling within the upper limit of the previ-
ously reported range,3 the env phylogeny did not support
linkage. Detailed analyses of the env sequences were made
available to selected expert reviewers from JAMA and
deemed robust. All phylogenies will be submitted for publi-
cation once study is completed.
Goldman and colleagues are correct that phylogenetic
analyses of putative transmission events should include con-
trol sequences drawn from epidemiologically relevant set-
tings and take into account time since seroconversion.4
These factors were taken into account in the PARTNER study.
The study design was such that patients were sampled never
later than 6 to 8 months from seroconversion. Constraints
dictated by the terms of the ethical approvals and need to
protect patients’ confidentiality mean that the phylogenetic
investigations must not reveal the geographic origin of the
specimens undergoing analysis. Although we recognize the
importance of disclosing to public scrutiny our detailed
analyses, the confidential data we hold in this respect are
entirely consistent with the reported conclusions of the
PARTNER study.
We are confident that clinicians are able to interpret
the data and counsel patients appropriately, taking into
account individual circumstances and tolerance of any risk,
however small.
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Therapy for Cellulitis
To the Editor In their comprehensive review of cellulitis,
Drs Raff and Kroshinsky discussed the limited role of
culture in making the diagnosis.1 Although a majority of
cases of severe nonsuppurative cellulitis (even those pre-
senting with sepsis) are due to β-hemolytic streptococcus,2
antibiotic therapy in the inpatient setting often is unneces-
sarily broad, covering methicillin-resistant Staphylococcus
aureus (MRSA) and various gram-negative bacteria. The lack
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of culture data can lead to continued extended broad-
spectrum antimicrobial use in these patients. The use of
serological testing for β-hemolytic streptococcus is under-
used in this setting but can lead to diagnosis of an etiologi-
cal agent in up to 40% of these patients, and subsequently,
to the fairly rapid simplification of treatment regimen to a
narrow-spectrum agent such as penicillin G.2-4 Use of sero-
logic testing thus has implications both for cost of antimi-
crobials and effective antimicrobial stewardship.
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To the Editor There are several statements in the review of
cellulitis1 that requirediscussion.First, the authors stated that
MRSA should be considered as the causative organism of pu-
rulent infections in knownhigh-risk populations, such as ath-
letes, men who have sex with men, prisoners, etc. However,
theconcept thatpatients in theUnitedStateswithcommunity-
associatedMRSAhave risk factors for acquiringanSaureus iso-
late with methicillin resistance is outdated, as most children
and adults with community-associated MRSA infection lack
any risk factors and have not had contact with persons with
such exposures.2 MRSA should not be excluded based on the
lack of such risks.
Second, for nonpurulent cellulitis, both clindamycin
and trimethoprim-sulfamethoxazole should be considered
as alternative first-line treatments. In a clinical trial of
524 patients with purulent and nonpurulent cellulitis, these
2 agents had similar efficacy and tolerability in the sub-
group of 280 patients with nonpurulent cellulitis.3 Many of
these patients had 1 or more signs of systematic inflamma-
tory response syndrome; data on patients with severe infec-
tion treated with these agents are lacking, and thus, these
agents may not be appropriate for this population. Although
the efficacy of these agents compared with other recom-
mended antibiotics for cellulitis are lacking, in patients with
mild to moderate nonpurulent cellulitis, trimethoprim-
sulfamethoxazole and clindamycin should be considered
acceptable agents.
Third, for purulent cellulitis, it is unclear why clindamy-
cin should be relegated to being an alternative antibiotic for
patients with penicillin allergy. The efficacy, tolerance, and
safety of clindamycin are undistinguishable to those of
trimethoprim-sulfamethoxazole for purulent cellulitis.3
Concerns over Clostridium difficile were cited by the
authors, but C difficile is uncommon in patients with mild-
to-moderate disease. In the trial cited above,3 none of the
264 patients receiving clindamycin acquired C difficile as a
complication (95% CI, 0.0%-1.4%). C difficile incidence is
influenced by patient characteristics, such as recent hospi-
talization and advanced age,4 and the majority of patients
with skin infections are not hospitalized5 and thus are at
relatively low C difficile risk.
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To the EditorWe would like Drs Raff and Kroshinsky1 to com-
ment on 3 additional issues in the management of cellulitis.
First,wewere surprisedby their omissionof thebeneficial role
of adjunctive corticosteroids, which in a randomized double-
blind trial of erysipelas (the European synonym for cellulitis)
acceleratedclinical response, shortenedhospital stay, andmay
have reduced recurrence rates.2,3
Second, we wonder if 24 hours is too soon to assess re-
sponse to therapy, because the inflammation of many pa-
tients worsens temporarily, presumably from the release of
streptococcal toxins into the dermis and subcutaneous tis-
sue. Third,wewould like the authors to comment on the util-
ity of the common clinical practice of outlining the erythema
with a pen, a practice we believe is fundamentally flawed be-
cause the border is often indistinct with skip areas and be-
cause erythema often extends beyond this border in patients
who eventually respond to therapy.
Juan N. Lessing, MD
Steven McGee, MD
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In Reply Dr Kak highlights the challenge of treating cellulitis
given the lack of culture data and the possibility of using
surrogate biomarkers instead. In patients with group A
streptococcal infections, although the antistreptolysin O
response usually appears within 1 week and peaks 3 to 6
weeks after the infection, the decline in titers is less well
characterized,1 and elevated titers can persist long after ini-
tial infection. Also, many patients have recurrent bouts of
cellulitis, which may further complicate titer results. These
difficulties in interpreting a single antistreptolysin O titer
led the World Health Organization to recommend that 2
assays performed 10 to 14 days apart with a 4-fold rise in
titer between samples be used to diagnose recent group A
streptococcal infection,2 which is impractical for patients
with acute cellulitis.
Dr Miller notes the high prevalence of community-
acquiredMRSAinchildrenandadultsevenwithoutknownrisk
factors.We agree thatMRSA should not be excluded based on
the absence of risk factors alone and advocate for use of hos-
pital antibiograms,3 which are compilations of aggregate an-
timicrobial susceptibility data, along with risk factors to in-
fluence empirical treatment.
Miller cites a trial of treatment of nonpurulent cellulitis
withclindamycinor trimethoprim-sulfamethoxazole thatdem-
onstrated similar cure rates and adverse event rates. How-
ever, another trial found that theadditionof antibiotics against
community-associated MRSA did not improve outcomes in
nonpurulent cellulitis,4 suggesting that although antibiotics
against community-associatedMRSA canbe effective, the or-
ganism does not cause nonpurulent cellulitis to a significant
degree.Therefore empirical treatmentwithantibiotics against
streptococci andmethicillin-sensitive S aureus is reasonable.
Community-associatedMRSA is more commonly foundwith
abscess or purulent cellulitis; however, purulent cellulitis ac-
counts for less than 10% of all purulent skin infections.6 The
Infectious Diseases Society of America guidelines recom-
mend treatment of most cases of cellulitis with antibiotics
against streptococci, not MRSA.
In our review, clindamycinwas listed as an alternative for
purulent cellulitis in patients who were allergic to penicillin
primarily due to the concern for clindamycin resistance in
MRSA, whichwas found in nearly 27% ofMRSA isolates in 43
USmedical centers.5 Incontrast,only2%ofMRSAisolateswere
resistant to trimethoprim-sulfamethoxazole. Ultimately, the
use of clindamycin alone for MRSA should be based on local
resistance patterns.
Our review focused on nonerysipelas and we were un-
able to commentonseveral interestingaspectsof cellulitis and
its treatment, including the roleof systemic steroids.Data sup-
port the adjunctive use of steroidal and nonsteroidal anti-
inflammatory medications to address the strong inflamma-
tory response to theorganisms.6Timing,dosage, andduration
of use of these agents require further exploration.
Some, but not all, patients respond within the first 24
hours of therapy, and as such we recommended a range for
the window to reevaluate of 24 to 48 hours. We agree that by
definition nonerysipelas cellulitis has indistinct margins.
However, outlining the border of inflammation has value
because there is a margin that can be identified between
involved and uninvolved skin, and more clearly defining this
can be helpful to monitor disease progression vs improve-
ment with treatment, especially in situations of physician
turnover or patient-led assessment. Skip areas do arise, and
we outline these areas as well. In the age of electronic medi-
cal records, this practice may be replaced with the inclusion
of serial, high-quality photographs.
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CORRECTION
Error in Abstract: In theOriginal Investigation entitled “Effect of Postextubation
High-FlowNasal Cannula vsNoninvasiveVentilation onReintubation andPostex-
tubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial,”1
publishedonlineOctober5, 2016, and in theOctober 18, 2016,print issueof JAMA,
therewas an error in thewording of the second sentence of the abstract’s Results
section.Thesentenceshouldreadas follows: “Sixty-sixpatients (22.8%) inthehigh-
flow group vs 60 (19.1%) in theNIV groupwere reintubated (absolute difference,
−3.7%; 95% CI, −9.1% to ); 78 patients (26.9%) in the high-flow group vs 125
(39.8%) in theNIV group experiencedpostextubation respiratory failure (risk dif-
ference, 12.9%; 95% CI, 6.6% to).” This article was corrected online.
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